New directions in cell therapy: iPSC platforms and in vivo reprogramming
This image was generated by AI and may not depict real events.
Researchers are making progress in cell therapy with the development of iPSC-derived cellular products and in vivo reprogramming techniques. These advancements have the potential to revolutionize regenerative medicine and oncology by enabling the creation of safe and effective therapeutic products.
Cell therapy is advancing with iPSC-derived products and in vivo reprogramming. Induced pluripotent stem cells can be guided to differentiate into various cell types. Researchers use molecular tools like growth factors and cytokines to control cell fate. In vivo reprogramming converts one cell type into another within the body, eliminating the need for cell extraction and reinfusion. This approach has shown promise in preclinical studies, including the conversion of cardiac fibroblasts into functional cardiomyocytes. In vivo CAR-T therapy is also being developed, using lipid nanoparticles or viral vectors to deliver genetic instructions to T cells.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.